Immunome Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update

– IMM-BCP-01: Isolated antibodies capable of neutralizing SARS-CoV-2 variants, including the South African variant (B.1.351), in pseudovirus testing –

– IMM-ONC-01: Advanced proprietary antibody against IL-38 into IND-enabling studies –

– Raised $44.9 million in gross proceeds in NASDAQ IPO –

– Program updates expected in 2Q 2021 –

See more here